Ginkgo Bioworks Holdings Inc (DNA)

[Cameo Brien]

Ouch

[trade2brich]

As long as it RS and holds PPS….outstanding shares get reduced

[resx18]

Hearing R/S coming .. $DNA

[Cameo Brien]

Mucho shares

[ItsMyOption]

If one looks at the many pages of insider selling I am surprised DNA is not lower. It looks to me that they may be done selling and DNA should start going up.
Insiders - why all the selling? = https://www.etrade.wallst.com/v1/stocks/ownership/insiders.asp?symbol=DNA

[trade2brich]

See how the pps holds for tomorrow or….friday profit taking

[trade2brich]

Looking good here

[resx18]

SONIC BOOM $DNA

[nicehit]

On fire! That Google deal will move this up to $10 in early 2024!

[trade2brich]

ARK still buying up shares!

[resx18]

Looking good here $DNA

[resx18]

#LFG $DNA #WeHaveThePower

[trade2brich]

What’s going on here with the dip?

[Wallstveteran]

News is OUT!! +8% Pre Market https://lussosnews.com/ginkgo-bioworks-dna-partners-with-merck-to-revolutionize-biologic-manufacturing/

[AJ Freely]

$DNA - 👆Up 5.8% Pre-Market/ Current Price $2.17
Announces Collaboration with Merck to Improve Biologic Manufacturing

[Monksdream]

Ginkgo Bioworks Holdings Inc NYSE: DNA

GoSymbol lookup
Materials : Chemicals | Small Cap GrowthCompany profile
Ginkgo Bioworks Holdings, Inc. provides horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its cell programs are designed to enable biological production of products as diverse as therapeutics, key food ingredients and chemicals derived from petroleum. Its Foundry segment consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two assets: the Foundry, biology lab facilities, enabled by investment in workflows, custom software, robotic automation, and data science and analytics. Its Biosecurity segment consists of COVID-19 testing products and services primarily provided to public health authorities. It also owns the adeno-associated virus capsid discovery and engineering platform assets.

[1hot toddy]

COMPANY HAS 1.2 BILLION DOLLARS $$$$$$$$$$

[seventhcircle]

$dna going green

[seventhcircle]

$dna looks like a little dip this morning.

[seventhcircle]

yep this things a beast

[wiredawg]

Looks like DNA is getting a lotta love from this news...

[seventhcircle]

https://finance.yahoo.com/news/ginkgo-bioworks-awarded-darpa-contract-110100431.html

[seventhcircle]

news hit this morning must of leaked

[AJ Freely]

$DNA - UP 3% Pre-Market/ Current Price $2.43
Awarded DARPA Contract to Reimagine the Manufacturing of Complex Therapeutic Proteins

[Noseyrosey]

thank you!

[seventhcircle]

markets all up big been noticing cash flowing into small caps.

[Noseyrosey]

why the price action today?

[seventhcircle]

$DNA BOOMAGE

[1hot toddy]

yr u bringing the negativity? i just ask . i know what a non disclosure is nif thats what u talking about

[Monksdream]

DNA that awful Cathie Wood continues buying
Ginkgo Bioworks Holdings Inc NYSE: DNA

GoSymbol lookup
Materials : Chemicals | Small Cap GrowthCompany profile
Ginkgo Bioworks Holdings, Inc. provides horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its cell programs are designed to enable biological production of products as diverse as therapeutics, key food ingredients and chemicals derived from petroleum. Its Foundry segment consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two assets: the Foundry, biology lab facilities, enabled by investment in workflows, custom software, robotic automation, and data science and analytics. Its Biosecurity segment consists of COVID-19 testing products and services primarily provided to public health authorities. It also owns the adeno-associated virus capsid discovery and engineering platform assets.

[Monksdream]

DNA that awful Cathie Wood continues buying
Ginkgo Bioworks Holdings Inc NYSE: DNA

GoSymbol lookup
Materials : Chemicals | Small Cap GrowthCompany profile
Ginkgo Bioworks Holdings, Inc. provides horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its cell programs are designed to enable biological production of products as diverse as therapeutics, key food ingredients and chemicals derived from petroleum. Its Foundry segment consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two assets: the Foundry, biology lab facilities, enabled by investment in workflows, custom software, robotic automation, and data science and analytics. Its Biosecurity segment consists of COVID-19 testing products and services primarily provided to public health authorities. It also owns the adeno-associated virus capsid discovery and engineering platform assets.

[trade2brich]

You are an a-hole is u didn’t realize the typo.

[trade2brich]

Obviously a typo

[1hot toddy]

whats nda????????

[trade2brich]

NDA is a home-run. Once it flies take out your principal investment. The rest is gold.

[seventhcircle]

$DNA had a great start this morning. Just needs to hold it's gains for the next leg.

[trade2brich]

ARK - another 1.7mil shares today

[WallStreetCash]

$DNA Ginkgo Bioworks Holdings Inc., "the most advanced technology on the planet." is most definitely becoming a huge part of everyones future. Some of our many Institutional investors, holding huge positions in $DNA , like Ballie Gifford & Co., ARK Investment management, Blackrock fund, just to name a few. Some of our many partners Boehringer Ingelheim, Bayer, Allonia, just to name a few. Some analysts believe that DNA could reach $1,000 per share in the future, but this is a very optimistic view (of which in my humble opinion see happening soon). More conservative analysts believe that DNA could reach $50 per share in the next few years. Furthermore their business formula getting initial funds upfront, then initiating this Huge Giant Octopus sucking constantly from every orifices....

[trade2brich]

ARK - another 1mil shares today

[trade2brich]

I am not day trading. This is a “long term” grand slam.

[KeepOn]

On the move.

[Porterhouse10]

Til it's NOT

[trade2brich]

Inching up

[trade2brich]

ARK and Cathy bought 3.7 million shares today…..

[trade2brich]

I agree. This thing is going to go BOOM one day and there will be no looking back

[WallStreetCash]

Earnings 5/10 DNA Ginkgo Bioworks is a Paradigm Shift for sure. Its just a matter of when. 100X maybe 1000X or more in my opinion. Do your own due diligence, prior to spending your money. This is a MONSTER!!!!

[jgrabar]

GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA) F/K/A SOARING EAGLE ACQUISITION CORP. (NASDAQ: SRNG) AFTER SECURITIES FRAUD CLASS ACTION SURVIVES MOTION TO DISMISS

A federal securities class action complaint against Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) F/K/A Soaring Eagle Acquisition Corp. (NASDAQ: SRNG) and certain of its officers has survived a motion to dismiss.
Current long-term Ginkgo shareholders who acquired shares via the Soaring Eagle SPAC, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever.

https://grabarlaw.com/the-latest/ginkgo-bioworks-shareholder-investigation/

[seventhcircle]

DNA

[Talc Moan]

Oh look another Filing. More dilution. 148,914,967 additional shares of the Company’s Class A common stock, $0.0001 par value per share (the “Class A Common Stock”) and 148,914,967 additional shares of the Company’s Class B common stock

[Talc Moan]

DNA Ginkgo Is a share selling Scam that ARKK keeps averaging down. They will reverse split or be delisted once under a buck and sent to otc markets.